<i>In Vitro</i> Antifungal Activity of Manogepix and Other Antifungal Agents against South African <i>Candida auris</i> Isolates from Bloodstream Infections-Reference-Cited by-同舟云学术

In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections

Published:2022-02-23 Issue:1 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Maphanga Tsidiso G.¹^ORCID,Mpembe Ruth S.¹,Naicker Serisha D.¹,Govender Nelesh P.¹²³⁴^ORCID,

Affiliation:

1. National Institute for Communicable Diseases (Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses), National Health Laboratory Service, Johannesburg, South Africa

2. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

3. Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

4. Medical Research Council Centre for Medical Mycology, College of Medicine and Health, University of Exeter, Exeter, United Kingdom

Abstract

Since C. auris was first detected in South Africa in 2009, health care-associated transmission events and large outbreaks have led to this pathogen accounting for more than 1 in 10 cases of candidemia. A large proportion of South African C. auris isolates are highly resistant to fluconazole but variably resistant to amphotericin B and echinocandins.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01717-21

Reference33 articles.

1. Centers for Disease Control and Prevention (CDC). Tracking Candida auris countries from which Candida auris cases have been reported as of February 15 2021. https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html#historical.

2. Candida auris: Disinfectants and Implications for Infection Control

3. Potential Fifth Clade ofCandida auris,Iran, 2018

4. Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016–20171

5. Candida Auris, An Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind?

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MECANISMOS DE RESISTÊNCIA ANTIFÚNGICA: EXPLORAÇÃO DOS ASPECTOS MOLECULARES E GENÉTICOS;REVISTA FOCO;2024-09-02

2. Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris;Journal of Fungi;2024-06-06

3. A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin;Journal of Fungi;2024-05-20

4. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05-09

5. Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials;Cureus;2024-04-28